By: Mehdia Amini, MD
Recent reports of two deaths involving unauthorized retatrutide products and recalls of compounded tirzepatide underscore growing concerns about medication safety and regulatory oversight.
GLP-1–based therapies have transformed the treatment of obesity and metabolic disease.
As an endocrinologist, I have seen firsthand the impact of medications such as Wegovy and Zepbound. Patients describe meaningful improvements in their weight, metabolic health, mobility, and quality of life. For many, these treatments have been life changing.
Yet alongside these advances, a growing market for compounded and unapproved weight-loss injections has emerged, often blurring the distinction between FDA-approved medications and preparations that have not undergone the same regulatory scrutiny. Recent safety reports highlight why this distinction matters.
Two Reported Deaths Involving an Unapproved Weight-Loss Drug
In October 2026, CBS News reported that the FDA had received two reports of deaths involving products marketed as retatrutide.
One involved a 41-year-old woman who reportedly suffered cardiac arrest after obtaining the product from an unreliable source. The second involved a 49-year-old patient who reportedly developed severe dehydration and malnutrition before suffering cardiac arrest after purchasing a product through an online peptide vendor.
Although a definitive causal relationship has not been established, two deaths reported following the use of unauthorized experimental weight-loss products represent a serious safety concern - particularly when the identity, concentration, and purity of those products remain uncertain.
Retatrutide, developed by Eli Lilly, is an investigational medication targeting GLP-1, GIP, and glucagon receptors. While clinical trials have shown promising results, retatrutide is not FDA-approved and is not commercially available as an approved prescription medication. Promising clinical trial results do not establish that a medication is ready for unrestricted use.
Nevertheless, products marketed as retatrutide are being sold through unauthorized online vendors. The FDA has explicitly stated that retatrutide cannot legally be used in drug compounding under current federal law. Patients obtaining these products cannot be assured that they are receiving the pharmaceutical preparation studied in clinical trials - or even that the vial contains the substance advertised.
An Overlooked Concern: Patients May Not Know Their Medication Is Compounded
In my clinical practice, I have encountered patients who were unaware that they were receiving compounded GLP-1 medications rather than FDA-approved products. Some believed they were receiving the same medications sold as Wegovy or Zepbound. When products are marketed under familiar ingredient names such as semaglutide or tirzepatide, the distinction is not always clear.
Unlike FDA-approved medications, compounded drugs do not undergo the same premarket evaluation for safety, effectiveness, and manufacturing quality. Patients have a right to know what they are receiving. Informed consent should include a clear explanation of whether a medication is compounded, where it comes from, and what is known about its quality and safety.
Why I Do Not Routinely Recommend Compounded GLP-1 Medications
1. Uncertainty About Potency and Composition
FDA-approved medications undergo rigorous manufacturing and quality-control processes to ensure consistency in identity, strength, purity, and stability.
With compounded preparations, particularly those obtained through inadequately regulated sources, there may be uncertainty about the amount of active medication present. Insufficient potency may compromise effectiveness, while excessive potency increases the risk of adverse effects.
2. Purity, Sterility, and Stability
GLP-1 medications are peptide-based therapies whose molecular integrity is essential to their activity. Improper formulation, storage, or transportation can compromise stability, while inadequate manufacturing controls may introduce impurities or microbial contamination.
The FDA has also received complaints about compounded GLP-1 products arriving without adequate refrigeration, raising further questions about medication integrity.
3. Dosing Errors and Recent Product Recalls
Compounded GLP-1 medications may be dispensed in multidose vials with varying concentrations, requiring patients to measure doses using syringes rather than standardized delivery devices. The FDA has documented cases in which patients inadvertently administered five to twenty times their intended compounded semaglutide dose, resulting in severe gastrointestinal symptoms, dehydration, and, in some cases, hospitalization.
4. Unapproved Ingredients and Limited Clinical Evidence
Some compounded formulations contain alternative chemical forms, including semaglutide sodium or semaglutide acetate, whose equivalence to the FDA-approved active ingredient has not been established.
Others combine GLP-1 medications with additional ingredients, such as vitamin B12, without sufficient evidence demonstrating added benefit or safety.
Clinical trial results supporting medications such as Wegovy and Zepbound cannot automatically be applied to these alternative preparations.
Sharing an active ingredient does not establish equivalent pharmaceutical quality, safety, or clinical effectiveness.
The Financial Reality: Why Patients Seek Compounded Medications
Many insurance plans still exclude medications prescribed for weight management, and out-of-pocket costs can be substantial.
For patients who have experienced meaningful improvements in their health, losing access to an effective treatment because of cost can be deeply frustrating.
As an endocrinologist, I understand why patients seek more affordable options.
However, affordability should not come at the expense of medication quality or patient safety.
Patients facing financial barriers should discuss available options with their healthcare providers. Depending on eligibility, manufacturer savings programs, self-pay options for FDA-approved medications, or other evidence-based treatments may offer alternatives.
For anyone currently receiving GLP-1 injections, several questions are particularly important: Is my medication FDA-approved or compounded? Who manufactures it? Which pharmacy dispenses it? Has this exact preparation been evaluated for safety, quality, and effectiveness?
Patients who are uncertain about these answers should speak with their prescribing clinician.
Conclusion
GLP-1 therapies represent one of the most significant advances in modern metabolic medicine. Their benefits, however, depend on more than the active ingredient alone. Pharmaceutical quality, reliable dosing, appropriate clinical oversight, and informed consent are essential.
Legitimate compounding has an important role in medicine when an individualized preparation is medically necessary. It should not, however, be assumed equivalent to an FDA-approved medication.
Patients deserve access to life-changing treatments - and confidence in the safety and quality of what they are receiving.
At Evora Women’s Health, we understand the challenges of navigating GLP-1 treatment, insurance restrictions, and medication costs.
Our approach emphasizes individualized endocrine evaluation, evidence-based recommendations, and thoughtful consideration of treatment safety.
If you are considering GLP-1 therapy, have concerns about a compounded medication, or would like to explore your weight-management options, schedule a consultation with Dr. Mehdia Amini.
